Unsuppressed Viral Load Level in Public Health Facilities: Nonvirological Predictors among Adult Antiretroviral Therapy Users in Southwestern Ethiopia

References

• Stover J, Bollinger L, Izazola JA, Loures L, DeLay P, Ghys PD; Fast Track modeling working Group. What is required to end the AIDS epidemic as a public health threat by 2030? The cost and impact of the fast-track approach. PLoS One. 2016;11(5):e0154893.
   PubMed Web of Science ®Google Scholar
• Huerga H, Van Cutsem G, Farhat JB, et al. Progress towards the UNAIDS 90-90-90 goals by age and gender in a rural area of KwaZulu-Natal, South Africa: a household-based community cross-sectional survey. BMC Public Health. 2018;18(1):303. doi:10.1186/s12889-018-5208-0
   PubMed Web of Science ®Google Scholar
• Ehnri F. HIV Related Estimates and Projections for Ethiopia. Addis Ababa: FMoH; 2012:6–14.
   Google Scholar
• Nelson LJ, Beusenberg M, Habiyambere V, et al. Adoption of national recommendations related to use of antiretroviral therapy before and shortly following the launch of the 2013 WHO consolidated guidelines. Aids. 2014;28:S217–S224. doi:10.1097/QAD.0000000000000239
   Web of Science ®Google Scholar
• Louis FJ, Buteau J, François K, et al. Virologic outcome among patients receiving antiretroviral therapy at five hospitals in Haiti. PLoS One. 2018;13(1):e0192077.
   Web of Science ®Google Scholar
• Joseph Davey D, Abrahams Z, Feinberg M, et al. Factors associated with recent unsuppressed viral load in HIV-1-infected patients in care on first-line antiretroviral therapy in South Africa. Int J STD AIDS. 2018;29(6):603–610. doi:10.1177/0956462417748859
   PubMed Web of Science ®Google Scholar
• Uzande C, Edwards JK, Owiti PO, Maravanyika AT, Mashizha S, Mafaune PT. Are you suppressed? Viral load test coverage for people living with HIV in Mutare District, Manicaland Province, Zimbabwe, 2015–2017. BioRxiv. 2018;324350.
   Google Scholar
• Chhim K, Mburu G, Tuot S, et al. Factors associated with viral non-suppression among adolescents living with HIV in Cambodia: a cross-sectional study. AIDS Res Ther. 2018;15(1):20. doi:10.1186/s12981-018-0205-z
   Web of Science ®Google Scholar
• Jobanputra K, Parker LA, Azih C, et al. Factors associated with virological failure and suppression after enhanced adherence counselling, in children, adolescents and adults on antiretroviral therapy for HIV in Swaziland. PLoS One. 2015;10(2):2. doi:10.1371/journal.pone.0116144
   Web of Science ®Google Scholar
• Sayles JN, Rurangirwa J, Kim M, Kinsler J, Oruga R, Janson M. Operationalizing treatment as prevention in Los Angeles County: antiretroviral therapy use and factors associated with unsuppressed viral load in the ryan white system of care. AIDS Patient Care STDS. 2012;26(8):463–470. doi:10.1089/apc.2012.0097
   PubMed Web of Science ®Google Scholar
• World Health Organization. HIV Drug Resistance Report 2017; 2017.
   Google Scholar
• Charles M, Leger PD, Severe P, et al. Virologic, clinical and immunologic responses following failure of first-line antiretroviral therapy in Haiti. J Int AIDS Soc. 2012;15(2):17375. doi:10.7448/IAS.15.2.17375
   Web of Science ®Google Scholar
• Das M, Chu PL, Santos G-M, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One. 2010;5(6):6. doi:10.1371/journal.pone.0011068
   Web of Science ®Google Scholar
• Hailemariam S, Bune GT, Ayele HT. Malnutrition: prevalence and its associated factors in people living with HIV/AIDS, in Dilla University Referral Hospital. Arch Public Health. 2013;71(1):13. doi:10.1186/0778-7367-71-13
   PubMedGoogle Scholar
• Hull MW, Montaner J. Antiretroviral therapy: a key component of a comprehensive HIV prevention strategy. Curr HIV/AIDS Rep. 2011;8(2):85–93. doi:10.1007/s11904-011-0076-6
   PubMedGoogle Scholar
• Gagnon M, Guta A. HIV viral load: a concept analysis and critique. Res Theory Nurs Pract. 2014;28(3):204–227. doi:10.1891/1541-6577.28.3.204
   PubMed Web of Science ®Google Scholar
• Izudi J, Alioni S, Kerukadho E, Ndungutse D. Virological failure reduced with HIV-serostatus disclosure, extra baseline weight and rising CD4 cells among HIV-positive adults in Northwestern Uganda. BMC Infect Dis. 2016;16(1):614. doi:10.1186/s12879-016-1952-x
   Web of Science ®Google Scholar
• Mattson CL, Freedman M, Fagan JL, et al. Sexual risk behaviour and viral suppression among HIV-infected adults receiving medical care in the United States. AIDS. 2014;28(8):1203. doi:10.1097/QAD.0000000000000273
   Web of Science ®Google Scholar
• Council A. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents;2011.
   Google Scholar
• Boullé C, Guichet E, Kouanfack C, et al. Virologic failure and human immunodeficiency virus drug resistance in rural Cameroon with regard to the UNAIDS 90-90-90treatment targets. Open Forum Infect Dis. 2016;3(4):. doi:10.1093/ofid/ofw233
   Google Scholar
• Centers for Disease Control and Prevention. Evidence of HIV Treatment and Viral Suppression in Preventing the Sexual Transmission of HIV; 2018.
   Google Scholar
• Flynn AG, Anguzu G, Mubiru F, et al. Socioeconomic position and ten-year survival and virologic outcomes in a Ugandan HIV cohort receiving antiretroviral therapy. PLoS One. 2017;12(12):12. doi:10.1371/journal.pone.0189055
   Web of Science ®Google Scholar
• Chao C, Tang B, Hurley L, et al. Risk factors for short-term virologic outcomes among HIV-infected patients undergoing regimen switch of combination antiretroviral therapy. AIDS Res Hum Retroviruses. 2012;28(12):1630–1636. doi:10.1089/aid.2012.0005
   Web of Science ®Google Scholar
• Jorge AR, Jorge PB, Elsa GL, et al. Risk factors associated with virologic failure in HIV-infected patients receiving antiretroviral therapy at a public hospital in Peru. Rev Chilena Infectol. 2013;30(1):42.
   Web of Science ®Google Scholar
• Anude CJ, Eze E, Onyegbutulem HC, et al. Immuno-virologic outcomes and immuno-virologic discordance among adults alive and on anti-retroviral therapy at 12 months in Nigeria. BMC Infect Dis. 2013;13(1):113. doi:10.1186/1471-2334-13-113
   Web of Science ®Google Scholar
• Crabtree-Ramírez B, Villasís-Keever A, Galindo-Fraga A, Del Río C, Sierra-Madero J. Effectiveness of highly active antiretroviral therapy (ART) among HIV-infected patients in Mexico. AIDS Res Hum Retroviruses. 2010;26(4):373–378. doi:10.1089/aid.2009.0077
   PubMed Web of Science ®Google Scholar
• Meireles MV, Pascom AR; Duantiretroviral therapy e EC. Factors associated with early virological response in HIV-infected individuals starting antiretroviral therapy in Brazil (2014–2015): results from a large HIV surveillance cohort. J Acquir Immune Defic Syndr. 2018;78(4):e19. doi:10.1097/QAI.0000000000001684
   PubMed Web of Science ®Google Scholar
• Sabaté E, Sabaté E, editors. Adherence to Long-Term Therapies: Evidence for Action. World Health Organization; 2003.
   Google Scholar
• Hailu GG, Hagos DG, Hagos AK, Wasihun AG, Dejene TA. Virological and immunological failure of ART and associated risk factors among adults and adolescents in the Tigray region of Northern Ethiopia. PLoS One. 2018;13(5). doi:10.1371/journal.pone.0196259
   Web of Science ®Google Scholar
• Sang RK, Miruka FO. Factors associated with virologic failure amongst adults on antiretroviral therapy in Nyanza Region, Kenya. IOSR J Dent Med Sci. 2016;15(7):108–121. doi:10.9790/0853-15076108121
   Google Scholar